| Name | factor XIII (protein family or complex) |
|---|---|
| Synonyms | FSF; Factor XIII; Fibrin stabilizing factor; Fibrin stabilizing factors |
| Name | monochloroacetic acid |
|---|---|
| CAS | 2-chloroacetic acid |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 2896611 | Komori Y, Nikai T, Sakairi Y, Sugihara H: Characterization of clotting factors from Agkistrodon acutus venom. Int J Biochem. 1988;20(4):387-92. Cf-1 (C) and Cf-2 (T), like thrombin, rapidly activated factor XIII in the presence of ions, whereas Cf-2 (C) and Cf-1 (T) had little effect on factor XIII. These effects are shown by Cf-1 (C) and Cf-2 (T) forming a clot that remained insoluble in 8 M urea or 0.44 M monochloroacetic acid, whereas Cf-2 (C) and Cf-1 (T) formed a soluble clot in these agents. |
1(0,0,0,1) | Details |
| 1037151 | Ragaz S, Kemp G, Furlan M, Beck EA: Bleeding disorder with abnormal wound healing, acid-soluble clots and normal factor XIII. Thromb Haemost. 1976 Dec 31;36(3):537-41. The only detectable coagulation abnormality was rapid clot dissolution in 1% monochloroacetic acid. |
1(0,0,0,1) | Details |
| 234201 | Ikemori R, Gruhl M, Shrivastava S, Shanberge JN: Solubility fo fibrin clots in monochloroacetic acid. Am J Clin Pathol. 1975 Jan;63(1):49-56. Because of the low pH of monochloroacetic acid the pepsinogen is activated and the clots are digested, simulating the dispersion of a fibrin clot which occurs in the absence of fibrin-stabilizing factor (factor XIII). |
81(1,1,1,1) | Details |
| 514066 | Kitchens CS, Newcomb TF: Factor XIII. . Medicine. 1979 Nov;58(6):413-29. Clots made from recalcified plasma severely deficient in factor XIII are soluble in 5 M urea or 1% monochloroacetic acid. |
10(0,0,1,5) | Details |
| 610332 | Ukita M, Mikami K, Kitahara T, Kato M, Kani T, Yano Y: [Studies on the relationship between factor XIII activity and fibrin clot solubility test by urea and monochloroacetic acid (author's transl)] Nippon Ketsueki Gakkai Zasshi. 1977 Dec;40(6):963-8. |
6(0,0,1,1) | Details |
| 8571322 | Taubenfeld SM, Song Y, Sheng D, Ball EL, Matsueda GR: A monoclonal antibody against a peptide sequence of fibrinogen gamma chain acts as an inhibitor of factor XIII-mediated crosslinking of human fibrin. Thromb Haemost. 1995 Sep;74(3):923-7. Pre-incubation of fibrinogen or pooled human plasma with mAb 4A5, but not mAb D2 (specific for the carboxyl terminus of fibrin alpha-chains), resulted in clots which are soluble in either 5 M urea or 1% monochloroacetic acid. |
4(0,0,0,4) | Details |
| 1370210 | Fukue H, Anderson K, McPhedran P, Clyne L, McDonagh J: A unique factor XIII inhibitor to a fibrin-binding site on factor XIIIA. Blood. 1992 Jan 1;79(1):65-74. Her fibrin clots had approximately 70% gamma-gamma and no alpha polymer formation, under conditions where normal fibrin was fully cross-linked; the patient's clots were soluble in urea or monochloroacetic acid. |
3(0,0,0,3) | Details |
| 8247644 | Blanckaert D, Oueidat I, Chelala J, Loeuille GA, Delepoulle F: [Congenital deficiency of fibrin stabilizing factor [factor XIII)] . Pediatrie. 1993;48(6):451-3. The diagnosis is confirmed by the rapid dispersion of the clot in urea 5 M or monochloroacetic acid. |
2(0,0,0,2) | Details |
| 6126311 | Ghidalia W, Vendrely R, Montmory C, Coirault Y: Cross induced coagulations between human and crustacean clotting factors. Comp Biochem Physiol A Comp Physiol. 1982;72(4):741-5. Cross induced coagulations show that human factor XIII and crustacean coagulin are to some extent functionally equivalent and may be substituted for each other. 2. The coagulin catalyzed transamidation which stabilizes the clot and renders it insoluble in 1-5% monochloroacetic acid solutions seems to be the basic reaction of the clotting process in the animals in which coagulation occurs. 4. |
1(0,0,0,1) | Details |
| 12193985 | Meili EO: [Clinical course and management of severe congenital factor XIII deficiency]. Hamostaseologie. 2002 Feb;22(1):48-52. Diagnosis is made by the solubility of fibrin clots in urea (5 mol/l) or monochloroacetic acid (1-2%). A monthly prophylactic replacement therapy of 500 IE factor XIII concentrate was started. |
1(0,0,0,1) | Details |
| 2781519 | Roth RI, Chen JC, Levin J: Stability of gels formed following coagulation of Limulus amebocyte lysate: lack of covalent crosslinking of coagulin. Thromb Res. 1989 Jul 1;55(1):25-36. Chemical solubility studies of gelled lysates demonstrated rapid solubilization of gels in monochloroacetic acid, a property of clots that have not been covalently stabilized; but in contrast demonstrated resistance to solubilization by urea, a property of stabilized clots. Enzymatic assays for transpeptidase (Factor XIII-like) activity in either native or gelled Limulus lysates were negative. |
1(0,0,0,1) | Details |